Ligand Pharmaceuticals
LGND
258 hedge funds and large institutions have $1.96B invested in Ligand Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 108 increasing their positions, 62 reducing their positions, and 22 closing their positions.
527% more call options, than puts
Call options by funds: $3.56M | Put options by funds: $567K
86% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 22
74% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 62
8% more capital invested
Capital invested by funds: $1.81B → $1.96B (+$142M)
6% more funds holding
Funds holding: 243 → 258 (+15)
2.62% less ownership
Funds ownership: 99.22% → 96.59% (-2.6%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$31.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$10.3M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$7.58M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
+$4.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
-$21.2M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$20.6M |
| 3 |
FMI
F/M Investments
Washington,
District of Columbia
|
-$9.2M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$8.2M |
| 5 |
BlackRock
New York
|
-$6.05M |
LGND Hedge Fund Activity: Q4 2024 in Review
258 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2024, worth a combined $1.96B — up 7.8% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new LGND positions and 22 closed out — a net gain of 19 holders — while 108 added to existing stakes and 62 trimmed.
The largest buyer was Massachusetts Financial Services, opening a new position worth an estimated $31.3M. The largest seller was St. Denis J. Villere & Co, cutting an estimated $21.2M.
- 258 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2024, up from 243 in Q3 2024.
- Funds reported $1.96B of Ligand Pharmaceuticals stock for Q4 2024, up 7.8% quarter-over-quarter.
- 41 funds opened new Ligand Pharmaceuticals positions in Q4 2024 and 22 closed out, a net change of +19 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2024 was Massachusetts Financial Services, an estimated $31.3M added.
- The largest Ligand Pharmaceuticals seller in Q4 2024 was St. Denis J. Villere & Co, an estimated $21.2M sold.
Based on aggregated 13F filings for Q4 2024.